Genmab A/S (GMAB) posted performance results on Thursday for the first half of 2025, with revenue rising 19 percent year-over-year to $1.64 billion, up from $1.38 billion in the same period of 2024. The growth was largely fueled by increased royalties from key collaborations and higher net product sales of EPKINLY.
Royalty revenue jumped 24 percent to $1.38 billion, driven by stronger global net sales of DARZALEX by Johnson & Johnson and Kesimpta by Novartis. DARZALEX net sales surged 22 percent to $6.78 billion, up from $5.57 billion a year ago.
Net financial income declined to $119 million from $204 million, mainly due to lower foreign exchange gains and reduced interest income.
GMAB is currently trading at $22.70, up $1.18 or 5.51 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.